Boykin v. Genzyme Therapeutic Products, LP

93 F.4th 56
CourtCourt of Appeals for the First Circuit
DecidedFebruary 16, 2024
Docket23-1667
StatusPublished
Cited by6 cases

This text of 93 F.4th 56 (Boykin v. Genzyme Therapeutic Products, LP) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Boykin v. Genzyme Therapeutic Products, LP, 93 F.4th 56 (1st Cir. 2024).

Opinion

United States Court of Appeals For the First Circuit

No. 23-1667

CHARLES BOYKIN,

Plaintiff, Appellant,

v.

GENZYME THERAPEUTIC PRODUCTS, LP and PAUL BEAUSOLEIL,

Defendants, Appellees.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Richard G. Stearns, U.S. District Judge]

Before

Kayatta, Selya, and Gelpí, Circuit Judges.

Mitchell J. Notis and Law Office of Mitchell J. Notis on brief for appellant. Christopher B. Kaczmarek and Littler Mendelson, P.C. on brief for appellees.

February 16, 2024 SELYA, Circuit Judge. Plaintiff-appellant Charles

Boykin brought an employment-discrimination action against his

quondam employer, Genzyme Therapeutic Products, LP (Genzyme), and

one of its executives. Concluding that the plaintiff's allegations

of discrimination lacked an appropriate factual predicate, the

district court granted summary judgment in favor of the defendants.

The plaintiff appeals. After careful consideration, we affirm.

I

We briefly rehearse the relevant facts and travel of the

case. We draw our account from the summary judgment record.1 See

Mancini v. City of Providence, 909 F.3d 32, 37 (1st Cir. 2018).

In the process, we construe the facts in the light most flattering

to the party against whom summary judgment entered (here, the

plaintiff). See id. Relatedly, we draw all reasonable inferences

to that party's behoof. See id.

The plaintiff — an African-American male — began working

as a manufacturing supervisor for Genzyme in 2013. After some

time, he was promoted to the position of senior site planning

1 We note that — before the district court — the defendants moved to strike the plaintiff's statement of material facts. See D. Mass. R. 56.1. The district court allowed the motion "to the extent that any fact in [the plaintiff's statement of material facts] is inconsistent with the facts set forth in defendants' statement (which are deemed admitted given [the plaintiff's] failure to dispute the relevant paragraphs in his statement)." Boykin v. Genzyme Therapeutic Prods. LP, No. 21-10115, 2023 WL 4493514, at *1 n.1 (D. Mass. July 12, 2023). This ruling has not been challenged on appeal, and we do not discuss it further.

- 2 - analyst at Genzyme's Allston, Massachusetts facility. In this

role, he managed the cycle-count process at the Allston facility

and was responsible for investigating deviations from the

company's standard manufacturing processes at that site. The

plaintiff's direct manager was Michael Haepers, and Haepers's

superior was defendant-appellee Paul Beausoleil.

In 2017, issues surfaced relating to the plaintiff's job

performance. At different points in that year, Haepers and

Beausoleil separately expressed concerns to the plaintiff about

the pace at which he was resolving deviation investigations. And

on one occasion, Sebastian Bernhard, the head of finance at the

Allston facility, publicly criticized the plaintiff when Genzyme

failed an external cycle-count audit conducted by

PricewaterhouseCoopers. The plaintiff later reported Bernhard to

Genzyme's human resources administrators for alleged racial

discrimination, after which Bernhard apologized to the plaintiff.

In the winter of 2017 — while the plaintiff was mopping

up ice melt in the facility — Beausoleil allegedly told another

employee that "we finally have a job he [the plaintiff] can

handle." The plaintiff and a co-worker, both of whom overheard

this remark, regarded it as expressing a racial stereotype.

As the end of 2017 approached, Haepers and Beausoleil

communicated about the plaintiff's end-of-year review. In a

December 5 email, Haepers recommended that the plaintiff be given

- 3 - a rating of 3 on Genzyme's 9-block performance matrix. Although

the plaintiff had a "positive attitude and is always willing to

take on extra work or projects," Haepers explained, he also had a

tendency to "lose focus at times, especially as the process owner

for cycle counting." Haepers emphasized that the plaintiff "needs

[to] focus on his basic tasks (cycling counting and deviation

management)." Beausoleil responded, instructing Haepers to enter

the proposed rating into Genzyme's system but not to communicate

this rating to the plaintiff before it was finalized.

On March 20, 2018 — after the rating was finalized —

Haepers informed the plaintiff of it. Haepers told the plaintiff

that he initially gave him a rating of 5, but that Beausoleil

instructed him to reduce it to a 3. When the plaintiff asked why

Beausoleil lowered his rating, Haepers allegedly stated that

Beausoleil believed that the plaintiff was "making too much money."

In addition to rendering the plaintiff ineligible for a salary

increase and a bonus, the 3 rating required him to enter into an

Individual Improvement Plan. But before the plaintiff received

any such plan, he requested and received a medical leave of

absence. He never returned to work at Genzyme.

On January 22, 2021, the plaintiff sued Genzyme and

Beausoleil in the United States District Court for the District of

Massachusetts. His complaint alleged that the defendants engaged

in unlawful racial discrimination, racial harassment, and

- 4 - retaliation in violation of the Civil Rights Act of 1866 (counts

1 and 2), 42 U.S.C. § 1981, Title VII of the Civil Rights Act of

1964 (count 3), 42 U.S.C. §§ 2000e-2000e17, and the employment

discrimination provisions of Massachusetts law (counts 4 and 5),

Mass. Gen. Laws ch. 151B, § 4.

Following the completion of discovery, the defendants

moved for summary judgment. See Fed. R. Civ. P. 56(a). Although

the plaintiff opposed the motion, the district court granted it.

See Boykin v. Genzyme Therapeutic Prods. LP, No. 21-10115, 2023 WL

4493514, at *4 (D. Mass. July 12, 2023). Applying the burden-

shifting framework set forth in McDonnell Douglas Corp. v. Green,

411 U.S. 792, 802-05 (1973), the district court concluded that,

even if the plaintiff had endured a prima facie case of

discrimination, Genzyme had established a legitimate and

nondiscriminatory rationale for the adverse employment action.

See Boykin, 2023 WL 4493514, at *3. Moreover, the plaintiff had

not offered any sufficient proof that this rationale was

pretextual. See id. So, too, the district court found the

plaintiff's retaliation claim wanting because the plaintiff had

failed to proffer evidence sufficient to demonstrate "a causal

connection between the alleged protected conduct (filing a

complaint against Bernhard for racial discrimination) and the

adverse action (the poor performance review by Beausoleil)." Id.

This timely appeal ensued.

- 5 - II

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
93 F.4th 56, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boykin-v-genzyme-therapeutic-products-lp-ca1-2024.